Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) had its target price lowered by equities researchers at JPMorgan Chase & Co. from $34.00 to $30.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a "neutral" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s price target points to a potential upside of 6.42% from the company's previous close.
Several other research analysts have also recently weighed in on AGIO. Bank of America boosted their price objective on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a "buy" rating in a research report on Monday, September 21st. HC Wainwright boosted their target price on Agios Pharmaceuticals from $55.00 to $62.00 and gave the stock a "buy" rating in a research report on Friday, November 6th. Citigroup upped their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Weiss Ratings cut Agios Pharmaceuticals from a "sell (d)" rating to a "sell (d-)" rating in a report on Monday, November 9th. Finally, Truist Financial cut their target price on shares of Agios Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating on the stock in a research report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $41.62.
Check Out Our Latest Stock Analysis on Agios Pharmaceuticals
Agios Pharmaceuticals Stock Down 2.0%
Agios Pharmaceuticals stock traded down $0.57 on Friday, hitting $28.19. The company's stock had a trading volume of 195,109 shares, compared to its average volume of 1,059,293. Agios Pharmaceuticals has a one year low of $23.00 and a one year high of $44.09. The firm has a market cap of $1.69 billion, a P/E ratio of -4.46 and a beta of 0.66. The company has a fifty day moving average price of $32.76 and a 200-day moving average price of $31.88.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, topping analysts' consensus estimates of ($1.24) by $0.15. Agios Pharmaceuticals had a negative net margin of 264.76% and a negative return on equity of 34.63%. The company had revenue of $55.39 million during the quarter, compared to the consensus estimate of $51.65 million. Analysts anticipate that Agios Pharmaceuticals will post -5.72 EPS for the current year.
Insider Activity
In related news, insider Sarah Gheuens sold 7,866 shares of the business's stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $37.69, for a total transaction of $296,469.54. Following the completion of the transaction, the insider owned 54,645 shares in the company, valued at approximately $2,059,570.05. The trade was a 12.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 9,855 shares of company stock worth $371,112. 5.40% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Agios Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Nykredit A S acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at approximately $26,000. Three Bridge Wealth Advisors LLC acquired a new position in Agios Pharmaceuticals during the third quarter worth $27,000. Quantbot Technologies LP acquired a new position in Agios Pharmaceuticals during the second quarter worth $43,000. Integrated Wealth Concepts LLC bought a new position in Agios Pharmaceuticals in the second quarter valued at $47,000. Finally, Allworth Financial LP bought a new position in Agios Pharmaceuticals in the second quarter valued at $73,000.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments. Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.